### NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

**Single Technology Appraisal**

**Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer**

**Matrix of consultees and commentators**

<table>
<thead>
<tr>
<th>Consultees</th>
<th>Commentators (no right to submit or appeal)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Manufacturers/sponsors</strong></td>
<td>General</td>
</tr>
<tr>
<td>• Dendreon Corporation (sipuleucel-T)</td>
<td>• Allied Health Professionals Federation</td>
</tr>
<tr>
<td><strong>Patient/carer groups</strong></td>
<td>• Board of Community Health Councils in Wales</td>
</tr>
<tr>
<td>• Afiya Trust</td>
<td>• British National Formulary</td>
</tr>
<tr>
<td>• Black Health Agency</td>
<td>• Care Quality Commission</td>
</tr>
<tr>
<td>• Bob Champion Cancer Trust</td>
<td>• Commissioning Support Appraisals Service</td>
</tr>
<tr>
<td>• Cancer Black Care</td>
<td>• Department of Health, Social Services and Public Safety for Northern Ireland</td>
</tr>
<tr>
<td>• Cancer Equality</td>
<td>• Healthcare Improvement Scotland</td>
</tr>
<tr>
<td>• Equalities National Council</td>
<td>• Medicines and Healthcare products Regulatory Agency</td>
</tr>
<tr>
<td>• Everyman</td>
<td>• National Association of Primary Care</td>
</tr>
<tr>
<td>• HAWC</td>
<td>• National Pharmacy Association</td>
</tr>
<tr>
<td>• Helen Rollason Cancer Charity</td>
<td>• NHS Alliance</td>
</tr>
<tr>
<td>• Independent Cancer Patients Voice</td>
<td>• NHS Commercial Medicines Unit</td>
</tr>
<tr>
<td>Macmillan Cancer Support</td>
<td>• NHS Confederation</td>
</tr>
<tr>
<td>• Maggie’s Centres</td>
<td>• Scottish Medicines Consortium</td>
</tr>
<tr>
<td>• Marie Curie Cancer Care</td>
<td><strong>Comparator manufacturers</strong></td>
</tr>
<tr>
<td>• Muslim Council of Britain</td>
<td>• Actavis UK (docetaxel)</td>
</tr>
<tr>
<td>• Muslim Health Network</td>
<td>• Hospira UK (docetaxel)</td>
</tr>
<tr>
<td>• Orchid</td>
<td>• Janssen (abiraterone)</td>
</tr>
<tr>
<td>• PCaSO – Prostate Cancer Network</td>
<td>• Medac UK (docetaxel)</td>
</tr>
<tr>
<td>• Prostate Cancer UK</td>
<td>• Sandoz (docetaxel)</td>
</tr>
<tr>
<td>• Prostate Help Association</td>
<td>• Sanofi (docetaxel)</td>
</tr>
<tr>
<td>• South Asian Health Foundation</td>
<td>• Teva UK (docetaxel)</td>
</tr>
<tr>
<td>• Specialised Healthcare Alliance</td>
<td><strong>Relevant research groups</strong></td>
</tr>
<tr>
<td>• Tackle Prostate Cancer (formerly Prostate Cancer Support Federation)</td>
<td>• Cochrane Prostatic Diseases and Urologic Cancers Group</td>
</tr>
<tr>
<td>• Tenovus</td>
<td><strong>Professional groups</strong></td>
</tr>
<tr>
<td><strong>Professional groups</strong></td>
<td>• Association of Cancer Physicians</td>
</tr>
<tr>
<td>• British Association of Urological Nurses</td>
<td><strong>Consultees</strong></td>
</tr>
</tbody>
</table>

---

National Institute for Health and Care Excellence

Matrix for the technology appraisal of sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer

**Issue date:** April 2014
### Consultees
- British Association of Urological Surgeons
- British Geriatrics Society
- British Institute of Radiology
- British Prostate Group
- British Psychosocial Oncology Society
- British Society of Urogenital Radiology
- British Uro-Oncology Group
- Cancer Network Pharmacists Forum
- Cancer Research UK
- Pelican Cancer Foundation
- Prostate Cancer Advisory Group
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Health Forum
- United Kingdom Clinical Pharmacy Association
- United Kingdom Oncology Nursing Society
- Urology Foundation

### Commentators (no right to submit or appeal)
- Health Research Authority
- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Cancer Research Institute
- National Cancer Research Network
- National Institute for Health Research
- Ovarian & Prostate Cancer Research Trust
- Pro Cancer Research Fund
- Prostate Cancer Research Centre
- Research Institute of the Care of Older People

### Evidence Review Group
- School of Health and Related Research (ScHARR)
- National Institute for Health Research Health Technology Assessment Programme

### Associated Guideline Groups
- National Collaborating Centre for Cancer

### Associated Public Health Groups
- Public Health England
- Public Health Wales NHS Trust

---

Appendix C

<table>
<thead>
<tr>
<th>Consultees</th>
<th>Commentators (no right to submit or appeal)</th>
</tr>
</thead>
</table>
| - British Association of Urological Surgeons  
- British Geriatrics Society  
- British Institute of Radiology  
- British Prostate Group  
- British Psychosocial Oncology Society  
- British Society of Urogenital Radiology  
- British Uro-Oncology Group  
- Cancer Network Pharmacists Forum  
- Cancer Research UK  
- Pelican Cancer Foundation  
- Prostate Cancer Advisory Group  
- Royal College of General Practitioners  
- Royal College of Nursing  
- Royal College of Pathologists  
- Royal College of Physicians  
- Royal College of Radiologists  
- Royal Pharmaceutical Society  
- Royal Society of Medicine  
- Society and College of Radiographers  
- UK Health Forum  
- United Kingdom Clinical Pharmacy Association  
- United Kingdom Oncology Nursing Society  
- Urology Foundation  | - Health Research Authority  
- Institute of Cancer Research  
- MRC Clinical Trials Unit  
- National Cancer Research Institute  
- National Cancer Research Network  
- National Institute for Health Research  
- Ovarian & Prostate Cancer Research Trust  
- Pro Cancer Research Fund  
- Prostate Cancer Research Centre  
- Research Institute of the Care of Older People  |
| Others  
- Department of Health  
- NHS Eastbourne, Hailsham and Seaford CCG  
- NHS England  
- NHS Hartlepool and Stockton-on-Tees CCG  
- Welsh Government  |  

---

National Institute for Health and Care Excellence
Matrix for the technology appraisal of sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer

Issue date: April 2014
NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

**PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS**
Appendix C

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.